Ondine Biomedical Inc. (LSE:OBI) has announced a major milestone in the adoption of its Steriwave® technology, with British Columbia’s Interior Health Authority implementing the nasal photodisinfection therapy as the standard of care for all hip and knee replacement surgeries. This move makes Interior Health the second provincial health system in Canada to formally adopt the treatment.
The decision reflects growing recognition of Steriwave’s effectiveness in preventing post-surgical infections and delivering measurable cost efficiencies. By reducing infection rates and associated healthcare expenses, Steriwave aligns with provincial health objectives and strengthens Ondine’s foothold in the Canadian healthcare market.
This expanded adoption not only demonstrates the clinical value of Ondine’s light-based antimicrobial approach but also supports the company’s growth trajectory and long-term value proposition to shareholders.
About Ondine Biomedical Inc.
Based in Canada, Ondine Biomedical is a life sciences company at the forefront of antimicrobial innovation. The company develops and commercializes light-activated therapies—also known as photodisinfection—to combat infections, particularly those caused by antibiotic-resistant organisms. Its flagship product, Steriwave®, has received international regulatory approvals and is currently being deployed in healthcare settings to reduce surgical infection risks.
Leave a Reply